The streak is alive: management narrates back-to-back quarters of the same improvement and shows this quarter extended i
The model's full reasoning — Q3 2022 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management present the just-reported period as the latest step in an unbroken, still-running sequence of quarter-after-quarter improvement in the same part of the business, explicitly connecting this period to the immediately preceding period or periods as one continuing climb, with real current-period evidence that the sequence extended again? We need to check if management explicitly frames the quarter as another consecutive improvement. Look for phrases like "another quarter of growth", "improved again", "consecutive", etc. In the transcript, Tom Ernst says: "Our third quarter revenue grew 82% over the prior quarter." That is a quarter-over-quarter comparison. But is it part of a sequence? He also says "We are excited with this level of revenue growth" but does he say it's the latest in a series? He mentions "strong systems revenue growth of 89% quarter-over-quarter." But no explicit mention of consecutive quarters. He also says "We were able to deliver strong operating leverage despite the investment spending" and "adjusted EBITDA loss improved to a loss of 12% from a loss of 27% in the previous quarter." That is a sequential improvement in EBITDA loss (i.e., loss narrowed). But is that framed as a continuing sequence? He says "This was a 15 percentage point reduction in our adjusted EBITDA loss, which represented an improvement to a loss of 12% from a loss of 27% in the previous quarter." That is a sequential improvement. But does he say it's the latest in a run? He doesn't say "second consecutive quarter" or "another quarter of improvement." He just states the improvement. Also, the question requires that management explicitly connects this period to the immediately preceding period or periods as one continuing climb. The transcript does have quarter-over-quarter comparisons, but not necessarily a multi-quarter streak. For example, revenue grew 82% over prior quarter, but no mention of prior quarters. EBITDA loss improved from 27% to 12% loss, but again no mention of prior quarters. Look for any phrase like "another quarter of" or "consecutive". I don't see any. The only sequential comparisons are to the prior quarter, but not a chain of multiple periods.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| MFC | Manulife Financial Corporation | Q3 2023 | 2023-11-09 | C+ |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| WRB | W. R. Berkley Corporation | Q1 2022 | 2022-04-26 | B |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| FMS | Fresenius Medical Care AG & Co. KGaA | Q2 2018 | 2018-07-31 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| EPC | Edgewell Personal Care Company | Q3 2017 | 2017-08-08 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
MNKD · Q4 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES The transcript explicitly frames the just-reported quarter as the second consecutive (or second successive) profitable quarter for the endocrine business unit and for the Company overall. Management ties this directly to actual results in the current period (net income of $1 million GAAP and $7 million non-GAAP in Q4) following the prior 2023 quarter, and states they will continue to focus on growing the profitability of the endocrine business unit, which has had a positive contribution for two straight quarters.
CYBR · Q3 2021 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Udi Mokady explicitly frames Q3 as “another amazing quarter” that follows “an incredible second quarter,” using the single word “acceleration” to describe the quarter. He then quantifies the extension with concrete current-period metrics: subscription ARR growth accelerated to 131 % (reaching $139 million), total 38 % ARR growth (reaching $344 million), recurring revenue growth accelerated to 41 % ($89 million), and new logos accelerated to over 230.
MFC · Q3 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Roy Gori explicitly frames core ROE as having been ahead of the 15%+ medium-term target for the second consecutive quarter, while noting a 35% rise in core EPS this quarter (on top of steady year-on-year growth in core earnings over the past three quarters). Colin reinforces the sequential nature by stating that core ROE “increase[d] to 16.8%” this quarter.